Shareholder ABHMC II, LLC Files Intent to Sell $2.1M in Immunome Stock
IMNM has more than doubled off its 52-week low of $7.96.
Summary
A major shareholder has filed an intent to sell $2.1 million of Immunome stock, adding to recent insider selling activity.
Key Events · Ownership and Investor Activity · IMNM
-
Shareholder Files Intent to Sell
ABHMC II, LLC, a shareholder, filed a Form 144 indicating an intent to sell 100,000 shares of common stock, valued at approximately $2.1 million.
-
Adds to Recent Insider Distribution
This intent to sell contributes to a net insider distribution of over $3.7 million in the last 90 days, as reported in recent insider activity.
Analysis · IMNM · Life Sciences
A significant intent to sell $2.1 million worth of shares by a major shareholder, ABHMC II, LLC, creates a negative overhang on the stock. This filing contributes to a broader pattern of insider distribution, with net sales of over $3.7 million by insiders in the last 90 days.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMNM was trading at $21.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $7.96 to $27.65. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.